| HS Code | 535962 |
| Brand Name | IVF-C™ Inj. |
| Generic Name | Human Chorionic Gonadotropin (HCG) |
| Dosage Form | Injection |
| Strength | 5000 IU/vial |
| Route Of Administration | Intramuscular |
| Manufacturer | LG Chem |
| Indication | Infertility treatment |
| Packaging | Vial with solvent ampoule |
| Prescription Status | Prescription only |
| Storage Conditions | Store below 25°C, protect from light |
| Marketing Authorization | Approved in multiple countries |
As an accredited IVF-C™ Inj. factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | IVF-C™ Inj. packaging features a white box with blue accents, containing 1 vial of 5000 IU lyophilized powder and diluent. |
| Container Loading (20′ FCL) | IVF-C™ Inj. is shipped in 20′ FCL containers, securely packed to ensure product integrity and compliance with temperature regulations. |
| Shipping | IVF-C™ Inj. is shipped in temperature-controlled packaging to maintain stability. It requires refrigeration (2°C–8°C) and protection from light. Shipment is handled by certified carriers specialized in pharmaceutical products, ensuring timely delivery and compliance with regulatory guidelines. Handling instructions are included to ensure product integrity upon arrival. |
| Storage | **IVF-C™ Inj.** should be stored in a refrigerator at 2°C to 8°C. It should not be frozen. Protect the medication from light by keeping it in its original packaging until ready to use. Keep out of reach of children. Discard any unused solution. Always inspect the vial for particles or discoloration before administration. |
| Shelf Life | IVF-C™ Inj. has a shelf life of 24 months from the manufacturing date when stored below 25°C, protected from light. |
As the original manufacturer of IVF-C™ Inj., we support downstream partners engaged in advanced chemical and biologics production. Below, we outline practical, compliant applications in real-world industrial contexts, referencing the precise uses, regulatory standards, processing stages, and resulting finished products from our customers’ industries.
Pharmaceutical manufacturers use this raw material in the production of cemented injectable formulations for in vitro fertilization (IVF) protocols. It acts as a critical excipient and carrier for hormonal active pharmaceutical ingredients (APIs), serving specifically in the aseptic compounding stages for finished injectable drugs. Factories typically integrate this material during sterile fill-finish operations, demanding strict adherence to compendial requirements. Compliance with pharmacopoeial and GMP guidelines remains mandatory due to the injectable nature and reproductive medicine context. Our formulation technicians continually assist downstream clients with granular advice on raw material adjustment per batch-size and API loading.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Manufacturers of IVF and ART culture media select this material as a critical base for gamete and embryo-supporting fluids, owing to its physicochemical compatibility and certified raw material traceability. The compound must undergo filtration and QC release testing specified for media in direct contact with human cells and gametes, including endotoxin and sterility thresholds. Large-scale blenders calibrate component concentrations daily according to production lot analysis of osmolality and buffer consistency. Orders originate from media-makers preparing both ready-to-use and powder-concentrate product lines for hospital labs and fertility clinics.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
In compounding facilities, this ingredient supports stabilization and isotonic balance in large-volume parenteral nutrition admixtures for both human and veterinary clinical settings. Downstream processors demand documented absence of pyrogens, proteins, and nanoparticles to comply with infusion-grade regulations. Our QC documentation and full-batch analytics facilitate traceability audits for hospital or animal health customers. Integrators blend it as part of aqueous carriers in amino acid, carbohydrate, and electrolyte-based infusion bags used perioperatively or in intensive support.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
IVF-C™ Inj. functions as a stabilizer and isotonic balancing agent in bulk-manufactured liquid diagnostic reagents—especially those for reproductive hormone assays and immunodiagnostics. Diagnostic companies require each batch to conform to clinical laboratory reagent purity levels, demanding certificate-of-analysis traceability and absence of interfering contaminants. Technicians utilize it in diluent bases and immunoassay buffers to maintain consistent test performance over shelf life, directly impacting accuracy in clinical diagnostics.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Cell manufacturing facilities adopt this raw material for the formulation of GMP-grade suspension media used in adoptive cell transfer and cell expansion. Operators must verify batch purity and biocompatibility by dual-release checks before release for advanced therapeutic manufacturing. Process engineers calibrate concentrations to prevent osmotic shock and maintain high cell viability throughout culture, separation, and transport phases. The additive integrates during the early media formulation, after which the cell therapy products undergo sterile packaging and comprehensive lot traceability.
Industry compliance standards
Typical usage ratio
Downstream process integration
Final product types
Competitive IVF-C™ Inj. prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please contact us at +8618018036652 or mail to sales6@ascent-chem.com.
We will respond to you as soon as possible.
Tel: +8618018036652
Email: sales6@ascent-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Every batch of IVF-C™ Inj. embodies years of experience in peptide synthesis, tight environmental controls, and continuous investment in raw material integrity. People often imagine a chemical plant as a labyrinth of pipes and vats, but in practice, product outcomes depend on disciplined documentation, real-time analytics, and skillful human oversight. Our facility doesn’t cut corners—each vial of IVF-C™ Inj. runs through dozens of checkpoints before release. We know practitioners rely on transparent, credible product performance, which is why we maintain direct relationships with API suppliers. No consignment ever leaves the floor without defeating spec for purity and active content, and we never allocate inventory sourced from secondary channels.
At its core, IVF-C™ Inj. contains highly purified Chorionic Gonadotropin, manufactured to pharmaceutical standards that go beyond the minimum. Targeted for use within controlled ovarian stimulation, the formulation supports reproductive professionals in scheduled induction of ovulation. It directly benefits patients seeking reproductive assistance, offering a tightly calibrated dose profile with verified biological activity. For reproductive endocrinologists, reliable onset and predictable serum response mean less room for scheduling mishaps and fewer patient disappointments.
Some might wonder why investment in production precision matters so much. Having walked every aisle of the clean rooms, I see how even minor deviations impact critical patient moments. Any drift in temperature profile or miscalculated excipient blend can increase the risk of allergic response or lower dose reliability. We’ve proven, in hundreds of internal batch reviews and external audits, that strict adherence to purification and lyophilization protocols prevents protein denaturation. Our production leads study every alert pulled from in-line analyzers, and we trace any raw component back to the responsible farm or synthesis lot.
Most quality failures stem from shortcuts—open vials, questionable climate, unchecked cross-contamination. We resolved to prevent even minor lapses, with double redundancies throughout the entire filling and capping cycle. Cleaning validation isn’t just a regulatory checkbox for us; each staff member understands that their attention protects the patients at the end of this process. The value of real-world monitoring shows itself after months of shipments free from atypical particulate counts and microbial excursions.
Our IVF-C™ Inj. currently ships at a standardized specification: each vial contains a measured amount of highly purified hCG, lyophilized with select stabilizers, and presented for reconstitution in hospital or clinic environments. The bioassay release standard operates at no less than 95% of labeled potency up until expiry, with all excipients well within the current pharmacopoeial monographs. By working only with pre-qualified glassware and stoppering lines, we eliminate avoidable leachates and particulates.
Traceability matters most during product recalls or doctor inquiries. Each ampoule sports both datamatrix and human-readable batch identifiers, which link back to original QA certificates. We commit our technical team to explaining how each lot’s microanalysis links to the dosing patients receive today, not last quarter. In the unlikely event of a technical concern, the path of investigation leads smoothly from end-user report through plant records.
Generic hCG solutions often lack transparency—few manufacturers grant customers access to assay methods, lot history, or detailed COAs with extended test panels. For IVF-C™ Inj., every healthcare provider receives a full technical dossier upon request, and our qualified persons discuss any aspect of manufacture. There’s little value in a cheap ampoule if biological activity falls short, or if unknown bulking agents introduce risk. Every feedback channel, from hospital pharmacists to senior physicians, guides the next update of specifications. That’s why we recalibrate not only for compliance but for evolving clinical evidence and best practices.
Our own facility manages all stages, from API receipt through final packaging. No outside party controls the conditions that matter most for safety: temperature tracking, batch coding, or finishing. We fixed cold chain gaps by using GPS-traced containers and tamper-evidence seals—not because a specification requires it, but because we know, as manufacturers, how easily time and temperature can affect peptide integrity. Real clinical outcomes hinge on these details.
Healthcare professionals ask for consistent outcomes. Meeting this demand led us to expand our analytical bench, integrating HPLC purity testing, peptide mapping, and full-range endotoxin assays. We publish cumulative impurity trend data to major buyers because we have nothing to hide. Each intervention that improves impurity profiles or narrows active content variance finds its way into new SOPs. This attention to detail protects against dose failures, keeping practitioners and patients out of troubleshooting cycles.
Standards across manufacturers differ not just in raw ingredient sources but in blending and end-product fill accuracy. Our master techs calibrate fill pumps before every run, discarding outlier vials from each fill. By running at smaller batch sizes and slower line speeds, we manage to keep each vial at the declared fill mass, even under regulatory scrutiny. This hands-on approach comes from dealing with too many cases where underfilled or overdosed products led to regulatory action or, worse, clinical harm.
IVF timelines depend on more than good luck. Any delay or switch in medication can derail cycles planned months in advance, affecting both clinical staff workflow and patient lives. Our manufacturing schedule ties to planned clinic protocols, not speculative market moves. We actively seek input from major clinics and hospitals before building each quarterly batch plan. This keeps our production both responsive and aligned with the real needs of fertility specialists.
Direct distribution eliminates the confusion of parallel imports and unvetted stock points. Every carton ships from our certified plant under full temperature control, with delivery times confirmed before each order is scheduled. In rare cases where a local customs event causes delay, our logistics managers communicate in real time with clinics to arrange expedited replacement. Supply reliability owes a lot to pre-qualified suppliers, weather monitoring, and buffer stock investments at strategic locations near major demand hubs.
Hospitals and clinics often point out subtle variations in patient response—sometimes attributable to small differences in excipients, reconstitution protocols, or handling. We welcome frank feedback, treating each report as a case study rather than a complaint. One example: when a major IVF center presented findings on reconstitution ease and visibility during draw-up, our design team adjusted the lyophilization cycle to improve pellet characteristics. Small details change patient and provider experience. After we modified our excipient ratio, injection site tolerability improved, as did user feedback on reconstitution speed.
Each batch has an owner, and each owner reviews every incoming performance report. Our quality and production leads join quarterly roundtables with pharmacists and clinicians, discussing everything from packaging integrity to counsel on mixing steps. Doctors don’t want vague answers or delayed corrective action, so our direct manufacturing oversight shortens the loop from report to solution. We believe this is only possible when the manufacturer stands by the product in both boardroom and lab.
Global regulatory agencies raise expectations every year, issuing new requirements for impurity screening, product serialization, and patient-level documentation. We’ve learned to treat every new agency guidance as an opportunity for competitive advantage, not as a burden. From cleaning validation technologies to improved extractable-leachable studies, each upgrade to our process comes with validation data and field tracking reports. Our compliance teams stay tuned to input from clinicians on adverse event trends, using their input to fine-tune risk assessments.
As demand for medically assisted reproduction therapy increases, so does scrutiny. Market expansion must not outpace investment in reliability. Our integration of electronic batch records means no batch can be released without passing all gating criteria—manual signatures reinforce machine logs at every step, creating a dual-control system that keeps quality failings at bay. By owning our process data, we directly support site audits, regulatory inspections, or customer investigations that require historical trace.
Manufacturers offering finished injectables hold a special responsibility: no user should remain in doubt about safe handling, storage, or administration. Physicians receive technical guidance, practical mixing support, and real-time notifications of material changes. Updated leaflets reflect all formulation updates and handling advice, shaped by actual provider feedback. When new research emerges suggesting improved clinical use, our medical affairs team reviews application guidance and informs ordering physicians so that patient protocols reflect the latest science, not outdated assumptions.
Patients often feel apprehensive about moving to a new injectable. We support clinics in clear communication—explaining each batch’s journey and helping clarify how dose timing relates to therapeutic success. If questions arise about excipient origins or shelf life under variable refrigeration, our technical hotline offers answers straight from the production team, never a distant distributor or unqualified call center.
In a crowded market, true manufacturing expertise reveals itself in moments of stress—a pandemic lockdown, an API shortage, or a sudden regulatory shift. Our own team weathered raw material sourcing disruptions and adapted by developing local supplier backups, reducing lead times and avoiding batch cancellations. Facing increased freight obstacles, we shifted to premium temperature-controlled carriers, eating cost overruns to ensure clinics never had to cancel cycles due to shipping failure.
Many injectables on the market arrive after multiple handovers. Each additional handler introduces risk—broken cold chain, lost data, misapplied tracking codes. By preserving full custody and integrating robust serialization systems, we avoid grey market confusion and minimize the potential for errors. Our customers know that each ampoule originated at our own site, under real-time surveillance and verified by our trained staff.
While our current formulation remains stable, we continue to invest in process upgrades—advanced lyophilization control, real-time QA analytics, and faster, more secure logistics approaches. Regulatory feedback and shifting clinical demand determine where we channel capital investment, but process integrity never wavers. Our next-generation projects focus on reducing allergenic excipients, widening permissible storage temperatures, and improving reconstitution speeds based on direct clinical experience.
Lab findings and routine plant audits never replace field discoveries. Only after a new process runs smoothly under real-world demand conditions—and survives months of monitoring under varied climates—do we roll out changes as full improvements. By protecting patients and clinicians alike, we carry forward the original mission of IVF-C™ Inj.: delivering on purity, consistency, and peace of mind every time. Our commitment lies in standing accountable for each batch shipped, with open ears tuned to the evolving voices of those delivering and receiving care.